The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Open accessAbstract
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus (HCV) guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website (www.HCVGuidelines.org) disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection. Using a web-based system enables timely and nimble distribution of the HCV guidance, which is periodically updated in near real time as necessitated by emerging research data, recommendations from public health agencies, the availability of therapeutic agents, or other significant developments affecting the rapidly evolving hepatitis C arena. The value and utility of the online HCV guidance to the community of hepatitis C care providers throughout the world is evidence by the nearly 10 million pageviews by 1.5 million users originating from 228 countries and territories since the January 2014 launch of the website. A major update of the HCV guidance was released electronically in November 2019. This HCV guidance update summarizes and highlights key new or amended recommendations since the previous October 2018 print publication.1 The advent of safe, well-tolerated, and highly efficacious (>95% cure rate)2 direct-acting antiviral (DAA) therapy for HCV infection has ushered in an era in which elimination of hepatitis C is conceivable. In 2016, the World Health Organization (WHO) proposed a global health sector strategy to eliminate hepatitis C as a public health threat by 2030 and developed an action plan to facilitate this goal.3 In response to the WHO action plan, the National Academies of Science, Engineering, and Medicine (NASEM) developed a US strategy for the elimination of hepatitis C.4 Key elements of the elimination plan include improved detection of undiagnosed cases, increased linkage and access to care for newly diagnosed persons, and expanded treatment access. Many of the recommendations included in the latest update to the HCV guidance and highlighted herein align with and support the goals of the NASEM and WHO strategies to move from control to eventual elimination of hepatitis C. Topics addressed include universal and risk-based hepatitis C screening, simplified treatment algorithms for treatment-naive adults without cirrhosis or with compensated cirrhosis, hepatitis C management in the pediatric population, acute hepatitis C testing and management, and transplantation of organs from HCV-viremic donors into HCV-negative recipients. For detailed evidence reviews related to these topics and information addressing other aspects of HCV testing and management, see the online HCV guidance (www.HCVGuidelines.org). The HCV guidance was developed and is updated by a volunteer panel (representing the AASLD and the IDSA) of hepatology and infectious diseases clinicians with hepatitis C expertise using an evidence-based review of available data, including information presented at scientific conferences and published in peer-reviewed journals. Based on scientific evidence and expert opinion, recommendations are rated by the level of evidence (I, II, or III) and the strength of the recommendation (A, B, or C) using a system adapted from the American College of Cardiology and the American Heart Association.5, 6 See the original AASLD–IDSA hepatitis C guidance publication7 or the HCV guidance website for additional details about the processes and methods employed. All recommendations are reviewed and approved by the governing boards of the AASLD and the IDSA. The HCV guidance panel classifies therapeutic regimens as recommended, alternative, or not recommended based on patient factors (i.e., treatment-naive versus experienced, cirrhosis status, and comorbidities) and viral characteristics (i.e., genotype, subtype, resistance-associated substitutions). Recommended regimens are considered equivalent; alternative regimens are effective but, compared to recommended regimens, have potential disadvantages, limitations for use in certain patient populations, or less supporting data. The identification of risk factors associated with contracting HCV infection served as the basis for the risk-based hepatitis C screening recommendations issued by the US Centers for Disease Control and Prevention (CDC) in 1998.8 Although sensitive for the identification of persons with chronic HCV infection, risk-based screening failed to identify the majority of individuals with HCV infection due to both clinician and patient barriers.9-12 Analysis of the 2003-2010 National Health and Nutrition Examination Survey prevalence data demonstrated that approximately three fourths of individuals with chronic hepatitis C in the United States belonged to the 1945-1965 birth cohort.13 Based on these data, both the CDC and the US Preventive Services Task Force (USPSTF) recommended one-time hepatitis C sc
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–271 of 271
Tsui, J. I., Williams, E. C., Green, P. K., Berry, K., Su, F., & Ioannou, G. N. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.021 · Cited by 69
Bhamidimarri, K. R., Ladino, M. A., Pedraza, F., Guerra, G., Mattiazzi, A. D., Chen, L., Ciancio, G., Kupin, W. L., Martin, P. B., Burke, G. W., et al. (2017) · Transplant International · doi:10.1111/tri.12954 · Cited by 68
Long‐term outcome of vertically acquired and post‐transfusion hepatitis C infection in children
Rerksuppaphol, S., Hardikar, W., & Dore, G. J. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03463.x · Cited by 67
Hisada, M., OʼBrien, T. R., Rosenberg, P. S., & Goedert, J. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315396 · Cited by 66
Vanhommerig, J. W., Thomas, X. V., van der Meer, J. T. M., Geskus, R. B., Bruisten, S. M., Molenkamp, R., Prins, M., Schinkel, J., for the MOSAIC (MSM Observational Study for Acute Infection with hepatitis C) Study Group, Arends, J. E., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu695 · Cited by 66
Asselah, T., Lee, S. S., Yao, B. B., Nguyen, T., Wong, F. S.-H., Mahomed, A., Lim, S. G., Abergel, A., Sasadeusz, J. J., Gane, E. J., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30341-8 · Cited by 66
Gerber, L. H., Estep, M., Stepanova, M., Escheik, C., Weinstein, A. A., & Younossi, Z. M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.035 · Cited by 63
Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?
Hagström, H. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0343-0 · Cited by 63
Macı́as, J., Morano, L. E., Téllez, F., Granados, R., Rivero‐Juárez, A., Palacios, R., Ríos, M. J., Merino, D., Pérez‐Pérez, M., Collado, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.018 · Cited by 62
Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y., & Freedberg, K. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis382 · Cited by 61
Rosenthal, P. J., Schwarz, K. B., González‐Peralta, R. P., Lin, C., Kelly, D. A., Nightingale, S. L., Balistreri, W. F., Bansal, S., Jonas, M. M., Massetto, B., et al. (2019) · Hepatology · doi:10.1002/hep.30821 · Cited by 61
van Santen, D. K., van der Helm, J. J., del Amo, J., Meyer, L., Monforte, A. D., Price, M. A., Béguelin, C., Zangerle, R., Sannes, M., Porter, K., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.038 · Cited by 60
Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
McGlynn, E. A., Adams, J., Kramer, J. B., Sahota, A. K., Silverberg, M. J., Shenkman, E. A., & Nelson, D. R. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.4765 · Cited by 60
Natural history of vertically acquired HCV infection and associated autoimmune phenomena
Garazzino, S., Calitri, C., Versace, A., Alfarano, A., Scolfaro, C., Bertaina, C., Vatrano, S., Mignone, F., Licciardi, F., Gabiano, C., et al. (2014) · European Journal of Pediatrics · doi:10.1007/s00431-014-2286-6 · Cited by 58
Fabrizi, F., Dixit, V., & Messa, P. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23562 · Cited by 55
Hepatitis C Infection and Hepatocellular Carcinoma After Treatment of Childhood Cancer
Strickland, D. K., Jenkins, J. J., & Hudson, M. M. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200111000-00012 · Cited by 55
Tasillo, A., Yazdi, G. E., Nolen, S., Schillie, S. F., Vellozzi, C. J., Epstein, R. L., Randall, L. M., Salomon, J. A., & Linas, B. P. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003062 · Cited by 53
for the ANRS-Prevagay group, Vaux, S., Chevaliez, S., Saboni, L., Sauvage, C., Sommen, C., Barin, F., Alexandre, A. F., Jauffret‐Roustide, M., Lot, F., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3945-z · Cited by 53
Schmidt, A. J., Falcato, L., Zahno, B., Burri, A. V., Regenass, S., Müllhaupt, B., & Bruggmann, P. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-3 · Cited by 52
Dick, T. B., Lindberg, L. S., Ramirez, D. D., & Charlton, M. (2015) · Hepatology · doi:10.1002/hep.27920 · Cited by 51
Watts, T., Stockman, L., Martin, J., Guilfoyle, S., & Vergeront, J. M. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6642a3 · Cited by 49
Kucirka, L. M., Peters, T. G., & Segev, D. L. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.03.015 · Cited by 49
Schackman, B. R., Leff, J. A., Barter, D. M., DiLorenzo, M. A., Feaster, D. J., Metsch, L. R., Freedberg, K. A., & Linas, B. P. (2014) · Addiction · doi:10.1111/add.12754 · Cited by 48
Yang, X., Geng, X.-X., Huang, R.-G., Lin, J.-M., & Jiang, N. (2016) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.187603 · Cited by 48
Hwang, J., Yoon, H. M., Kim, J. R., Lee, J. S., Jung, A. Y., Kim, K. M., & Cho, Y. A. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19535 · Cited by 47
Younossi, Z. M., Stepanova, M., Jacobson, I. M., Asselah, T., Gane, E. J., Lawitz, E., Foster, G. R., Roberts, S. K., Thompson, A. J. V., Willems, B. E., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14423 · Cited by 46
Alem, S. A., Elsharkawy, A. M., Fouad, R., Adel, E., Abdellatif, Z., Musa, S., Nagy, A. M., Hussein, M. S., Yosry, A., & Esmat, G. (2017) · Journal of Medical Virology · doi:10.1002/jmv.24897 · Cited by 45
Dieperink, E. W., Ho, S. B., Heit, S., Durfee, J. M., THURAS, P. D., & Willenbring, M. L. (2010) · Psychosomatics · doi:10.1176/appi.psy.51.2.149 · Cited by 42
Hepatitis C Virus universal screening versus risk based selective screening during pregnancy
Waruingi, W., Mhanna, M. J., Kumar, D., et al. (2016) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-15915024 · Cited by 42
Flamm, S. L., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J. K., Horsmans, Y., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., et al. (2018) · Journal of Viral Hepatitis · doi:10.1111/jvh.13038 · Cited by 41
Nguyen, J. T., Barritt, A. S., & Jhaveri, R. R. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.12.012 · Cited by 41
Fontana, R. J., Sanyal, A. J., Ghany, M. G., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.058 · Cited by 40
Self-citationFoster, G. R., Dore, G. J., Wang, S., Grebely, J., Sherman, K. E., Baumgarten, A., Conway, B., Jackson, D., Asselah, T., Gschwantler, M., et al. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.11.007 · Cited by 40
Sawinski, D. L., Forde, K. A., Re, V. L., Goldberg, D. S., Cohen, J. B., Locke, J. E., Bloom, R. D., Brensinger, C. M., Weldon, J., Justine Shults, A., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.11.009 · Cited by 40
Selzner, N., & Berenguer, M. (2018) · Liver Transplantation · doi:10.1002/lt.25072 · Cited by 39
Hoz, R. M. L., Sandıkçı, B., Ariyamuthu, V. K., & Tanrıöver, B. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15496 · Cited by 38
Popping, S., Hullegie, S. J., Boerekamps, A., Rijnders, B. J. A., de Knegt, R. J., Rockstroh, J. K., Verbon, A., Boucher, C. A., Nichols, B. E., & van de Vijver, D. A. M. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210179 · Cited by 37
Franco, A., Moreso, F., Merino, E., Sancho, A., Kanter, J., Gimeno, A., Balibrea, N., Rodriguez, M., & Contreras, F. P. (2019) · Transplant International · doi:10.1111/tri.13410 · Cited by 36
Newsum, A. M., Stolte, I. G., van der Meer, J. T. M., Schinkel, J., van der Valk, M., Vanhommerig, J. W., Buvé, A., Danta, M., Hogewoning, A. A., Prins, M., et al. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.21.30540 · Cited by 34
An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C
Proeschold‐Bell, R. J., Patkar, A. A., Naggie, S., Coward, L., Mannelli, P., Yao, J., Bixby, P., & Muir, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1976-4 · Cited by 33
Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin
DeCarolis, D. D., Westanmo, A. D., Chen, Y.-C., Boese, A. L., Walquist, M. A., & Rector, T. S. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016660325 · Cited by 33
Janjua, N. Z., Darvishian, M., Wong, S., Yu, A., Rossi, C., Ramji, A. S., Yoshida, E. M., Butt, Z. A., Samji, H., Chong, M., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1307 · Cited by 33
Friebus‐Kardash, J., Gäckler, A., Kribben, A., Witzke, O., Wedemeyer, H. H., Treckmann, J. W., Herzer, K., & Eisenberger, U. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13146 · Cited by 33
Kim, A. Y., Nagami, E. H., Birch, C. E., Bowen, M. J., Lauer, G. M., & McGovern, B. (2012) · Hepatology · doi:10.1002/hep.26113 · Cited by 30
Aronson, I. D., Bennett, A. S., Marsch, L. A., & Bania, T. C. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00217 · Cited by 30
Toyoda, H., Atsukawa, M., Watanabe, T., Nakamuta, M., Uojima, H., Nozaki, A., Takaguchi, K., Fujioka, S., Iio, E., Shima, T., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14874 · Cited by 30
Schackman, B. R., Gutkind, S., Morgan, J. R., Leff, J. A., Behrends, C. N., Delucchi, K., McKnight, C. A., Perlman, D. C., Masson, C. L., & Linas, B. P. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.11.031 · Cited by 29
Shah, A. P., Cameron, A. M., Singh, P., Frank, A. M., & Fenkel, J. M. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12660 · Cited by 27
Medland, N., Chow, E. P. F., Bradshaw, C. S., Read, T. R. H., Sasadeusz, J., & Fairley, C. K. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2288-x · Cited by 27
Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City
Tieu, H., Laeyendecker, O. B., Nandi, V., Rose, R., Fernández, R. E., Lynch, B. A., Hoover, D. R., Frye, V. A., & Koblin, B. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200269 · Cited by 27
Liu, C., Huang, Y., Yang, S., Chang, C., Yang, S., Sun, H., Liu, C., Liu, W., Su, T., Yang, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32060-7 · Cited by 27
Coffin, P. O., Santos, G., Behar, E., Hern, J., Walker, J. E., Matheson, T., Kinnard, E. N., Silvis, J., Vittinghoff, E., Fox, R. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217471 · Cited by 26
New prospects for the treatment and prevention of hepatitis C in children
Ohmer, S., & Honegger, J. R. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000313 · Cited by 25
Delotte, J., Barjoan, E. M., Berrébi, A., Laffont, C., Benos, P., Pradier, C., Bongain, A., & for the ALHICE study group (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.829813 · Cited by 24
Kesen, O., Kani, H. T., Yanartaş, Ö., Aykut, U. E., Gök, B., Gündüz, F., Yilmaz, Y. N., Ozdogan, O. C., & Alahdab, Y. Ö. (2019) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2019.18679 · Cited by 23
Vizcaya, L. S., Wandeler, G., Fehr, J. S., Braun, D. L., Cavassini, M. L., Stoeckle, M. P., Bernasconi, E., Hoffmann, M., Rougemont, M., Béguelin, C., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy154 · Cited by 22
Page, E. E., & Nelson, M. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-2-189 · Cited by 21
Feng, H.-P., Caro, L., Fandozzi, C. M., Guo, Z., Talaty, J. E., Wolford, D. G., Panebianco, D. L., Iwamoto, M., Butterton, J. R., & Yeh, W. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1052 · Cited by 20
Artenie, A. A., Zang, G., Daniel, M., et al. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.05.033 · Cited by 19
Page, K. A., Leeman, L. M., Bishop, S., Cano, S., & Bakhireva, L. N. (2017) · Maternal and Child Health Journal · doi:10.1007/s10995-017-2316-x · Cited by 19
Harris, H., Mieli‐Vergani, G., Kelly, D. A., Davison, S. M., Gibb, D. M., Ramsay, M. E., & HCV National Register Steering Group (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3180dc9337 · Cited by 18
Puoti, M., Lorenzini, P., Cozzi‐Lepri, A., Gori, A., Mastroianni, C. M., Rizzardini, G., Mazzarello, G., Antinori, A., Monforte, A. D., Girardi, E., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.12.003 · Cited by 17
Valencia, J. A. S., Ryan, P., Álvaro‐Meca, A., Troya, J., Cuevas, G., Gutiérrez, J., & Moreno, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204795 · Cited by 15
Lee, S., Lee, T., Yang, S., Peng, Y., Yeh, H., & Chang, C. (2018) · Gastroenterology Research · doi:10.14740/gr971w · Cited by 13
Butler, K., Day, C., Dietze, P., Bruno, R., Alati, R., & Burns, L. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.06.008 · Cited by 12
Metwally, M. A., Zein, C. O., & Zein, N. N. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00352-4 · Cited by 12
Mangia, A., Milligan, S. C., Khalili, M., FAGIUOLI, S., Shafran, S. D., Carrat, F., Ouzan, D., Papatheodoridis, G., Ramji, A. S., Borgia, S. M., et al. (2019) · Journal of Hepatology · doi:10.1016/s0618-8278(19)30003-9 · Cited by 12
Sageshima, J., Troppmann, C., McVicar, J. P., Santhanakrishnan, C., de Mattos, A. M., & Perez, R. V. (2018) · Transplantation · doi:10.1097/tp.0000000000002096 · Cited by 9
Prognostic molecular markers in pediatric liver disease – Are there any?
Nielsen, J., Christensen, V. B., Borgwardt, L., Rasmussen, A., Østrup, O., & Kjær, M. S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.018 · Cited by 9
Hepatitis C in pregnant American Indian and Alaska Native women; 2003-2015
Nolen, L. D., O’Malley, J. C., Seeman, S. S., Bruden, D. J. T., Apostolou, A., McMahon, B. J., & Bruce, M. G. (2019) · International Journal of Circumpolar Health · doi:10.1080/22423982.2019.1608139 · Cited by 3
Research works printed but not linked: 125
- 2015, Comparison of risk‐based hepatitis C screening and the true seroprevalence in an urban prison system, J Urban Health, 92, 379, 10.1007/s11524-015-9945-4 · doi:10.1007/s11524-015-9945-4
- 2018, Healthcare value of implementing hepatitis C screening in the adult general population in Spain, PLoS One, 13
- 2016, Evaluation of the Centers for Disease Control and Prevention recommendations for hepatitis C virus testing in an urban emergency department, Clin Infect Dis, 62, 1059, 10.1093/cid/ciw074 · doi:10.1093/cid/ciw074
- 2016, Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department, Clin Infect Dis, 62, 1066, 10.1093/cid/ciw073 · doi:10.1093/cid/ciw073
- 2015, High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes, J Epidemiol Community Health, 69, 599, 10.1136/jech-2014-205070 · doi:10.1136/jech-2014-205070
- 2012, HCV seroconversion among never‐injecting heroin users at baseline: no predictors identified other than starting injection, Int J Drug Policy, 23, 415, 10.1016/j.drugpo.2012.02.002 · doi:10.1016/j.drugpo.2012.02.002
- 2016, Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care, Clin Microbiol Infect, 22, 459.e1, 10.1016/j.cmi.2016.01.009 · doi:10.1016/j.cmi.2016.01.009
- 2016, Identification and clinical management of persons with chronic hepatitis C virus infection—Cherokee Nation, 2012‐2015, MMWR Morb Mortal Wkly Rep, 65, 461, 10.15585/mmwr.mm6518a2 · doi:10.15585/mmwr.mm6518a2
- 2008, Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory, J Clin Virol, 42, 394, 10.1016/j.jcv.2008.02.015 · doi:10.1016/j.jcv.2008.02.015
- 1996, Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion, Alcohol Clin Exp Res, 20, 95A
- 2019, Liver stiffness assessed by ultrasound shear wave elastography from General Electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease, Ultraschall Med
- 2017, The negative impact of HBV/HCV coinfection on cirrhosis and its consequences, Aliment Pharmacol Ther, 46, 1054, 10.1111/apt.14352 · doi:10.1111/apt.14352
- 2019, Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the Electronically Retrieved Cohort of HCV‐Infected Veterans (ERCHIVES), Clin Infect Dis, 68, 857, 10.1093/cid/ciy697 · doi:10.1093/cid/ciy697
- 2017, Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents, Aliment Pharmacol Ther, 46, 992, 10.1111/apt.14328 · doi:10.1111/apt.14328
- 2018, Differential effect of HCV eradication and fibrosis grade on hepatocellular carcinoma and all‐cause mortality, Sci Rep, 8, 12146
- 2018, Impact of sustained virologic response on short‐term clinical outcomes in hepatitis C–related cirrhosis, Eur J Gastroenterol Hepatol, 30, 296, 10.1097/MEG.0000000000001032 · doi:10.1097/meg.0000000000001032
- 2017, Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct‐acting antivirals, J Hepatol, 66, 1173, 10.1016/j.jhep.2017.01.020 · doi:10.1016/j.jhep.2017.01.020
- 2019, Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis, Clin Exp Med, 19, 1, 10.1007/s10238-018-0536-z · doi:10.1007/s10238-018-0536-z
- 2017, Direct‐acting antiviral agents in the therapy of hepatitis C virus–related mixed cryoglobulinaemia: a single‐centre experience, Arthritis Res Ther, 19, 74, 10.1186/s13075-017-1280-6 · doi:10.1186/s13075-017-1280-6
- 2019, Rapid regression of B‐cell non‐Hodgkin's lymphoma after eradication of hepatitis C virus by direct antiviral agents, Case Rep Gastroenterol, 13, 336, 10.1159/000501546 · doi:10.1159/000501546
- 2019, miRNA‐26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon‐free antiviral therapy, Antivir Ther
- 2019, Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network, Hematol Oncol, 37, 160, 10.1002/hon.2575 · doi:10.1002/hon.2575
- 2012, Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection, Intern Med, 51, 2745, 10.2169/internalmedicine.51.8404 · doi:10.2169/internalmedicine.51.8404
- 2005, Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection, Aliment Pharmacol Ther, 21, 653, 10.1111/j.1365-2036.2005.02395.x · doi:10.1111/j.1365-2036.2005.02395.x
- 2005, Regression of advanced non‐splenic marginal zone lymphoma after treatment of hepatitis C virus infection, Leuk Lymphoma, 46, 1365, 10.1080/104281905001028289 · doi:10.1080/104281905001028289
- 2002, Regression of splenic lymphoma after treatment of hepatitis C virus infection, N Engl J Med, 347, 2168, 10.1056/NEJM200212263472614 · doi:10.1056/nejm200212263472614
- 2006, Improvement in quality of life measures in patients with refractory hepatitis C, responding to re‐treatment with pegylated interferon alpha ‐2b and ribavirin, Health Qual Life Outcomes, 4, 30, 10.1186/1477-7525-4-30 · doi:10.1186/1477-7525-4-30
- 2019, A systematic review and meta‐analysis of community and primary‐care‐based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments, BMC Health Serv Res, 19, 765, 10.1186/s12913-019-4635-7 · doi:10.1186/s12913-019-4635-7
- 2018, Direct‐acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment, Int J Drug Policy, 62, 74, 10.1016/j.drugpo.2018.10.003 · doi:10.1016/j.drugpo.2018.10.003
- 2017, Expansion of treatment for hepatitis C virus infection by task shifting to community‐based nonspecialist providers: a nonrandomized clinical trial, Ann Intern Med, 167, 311, 10.7326/M17-0118 · doi:10.7326/m17-0118
- 2018, Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals, Can J Gastroenterol Hepatol, 2018, 6095097
- 2016, Rapid decline of fasting glucose in HCV diabetic patients treated with direct‐acting antiviral agents, Clin Microbiol Infect, 22, 462.e1, 10.1016/j.cmi.2015.12.030 · doi:10.1016/j.cmi.2015.12.030
- 2016, Hypoglycemia in a diabetic patient during hepatitis C therapy, Hepatology, 63, 2065, 10.1002/hep.28137 · doi:10.1002/hep.28137
- 2017, Reduction in warfarin effect associated with sofosbuvir–velpatasvir, Am J Health Syst Pharm, 74, 1308, 10.2146/ajhp170324 · doi:10.2146/ajhp170324
- 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older, PLoS One, 14
- 2019, Integrated analysis of 8‐week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection, J Gastroenterol, 54, 752, 10.1007/s00535-019-01569-7 · doi:10.1007/s00535-019-01569-7
- 2019, Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1‐6: results of the HCV‐Target Study [Abstract 956], Gastroenterology, 156, S1220
- 2018, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis, J Gastroenterol, 53, 557, 10.1007/s00535-017-1391-5 · doi:10.1007/s00535-017-1391-5
- 2018, High SVR12 with 8‐week and 12‐week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1‐6 patients without cirrhosis, J Hepatol, 69, 293, 10.1016/j.jhep.2018.03.007 · doi:10.1016/j.jhep.2018.03.007
- 2019, Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase‐3, open‐label study in Russia and Sweden, Infect Dis (Lond), 51, 131, 10.1080/23744235.2018.1535186 · doi:10.1080/23744235.2018.1535186
- 2019, Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single‐arm, open‐label, phase 3 trial, Lancet Gastroenterol Hepatol, 4, 127, 10.1016/S2468-1253(18)30343-1 · doi:10.1016/s2468-1253(18)30343-1
- 2018, Resistance analysis in patients with genotype 1‐6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies, J Hepatol, 68, 895, 10.1016/j.jhep.2017.11.032 · doi:10.1016/j.jhep.2017.11.032
- 2019, Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry, Aliment Pharmacol Ther, 49, 1052, 10.1111/apt.15222 · doi:10.1111/apt.15222
- 2019, Effectiveness of therapy in 16,567 directly‐acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis, J Hepatol, 70, e131, 10.1016/S0618-8278(19)30231-2 · doi:10.1016/s0618-8278(19)30231-2
- 2019, Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir, Aliment Pharmacol Ther, 49, 99, 10.1111/apt.15043 · doi:10.1111/apt.15043
- 2019, Safety and efficacy of sofosbuvir‐based direct‐acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real‐world experience of a retrospective study, J Viral Hepat, 26, 316, 10.1111/jvh.13033 · doi:10.1111/jvh.13033
- 2018, High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection, Aliment Pharmacol Ther, 47, 1288, 10.1111/apt.14592 · doi:10.1111/apt.14592
- 2017, Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir‐based therapies, Clin Infect Dis, 64, 44, 10.1093/cid/ciw676 · doi:10.1093/cid/ciw676
- 2019, Glecaprevir/pibrentasvir for 8 weeks in treatment‐naive patients with chronic HCV genotypes 1‐6 and compensated cirrhosis: the EXPEDITION‐8 trial, J Hepatol
- 2016, 100% SVR4 with ABT‐493 and ABT‐530 with or without ribavirin in treatment‐naive HCV genotype 3‐infected patients with cirrhosis, J Hepatol, 64, S208, 10.1016/S0168-8278(16)00170-7 · doi:10.1016/s0168-8278(16)00170-7
- 2018, Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis, Gastroenterology, 155, 1120, 10.1053/j.gastro.2018.06.042 · doi:10.1053/j.gastro.2018.06.042
- 2018, Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis, Liver Int, 38, 443, 10.1111/liv.13534 · doi:10.1111/liv.13534
- 2019, Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study, Liver Int, 39, 1852, 10.1111/liv.14170 · doi:10.1111/liv.14170
- 2019, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real‐world cohort study, Hepatol Res, 49, 617, 10.1111/hepr.13328 · doi:10.1111/hepr.13328
- 2019, Real‐world experience of 12‐week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection, J Gastroenterol Hepatol
- 2019, Real‐world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3, J Hepatol, 70, 15, 10.1016/j.jhep.2018.09.018 · doi:10.1016/j.jhep.2018.09.018
- 2019, A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype‐2 chronic infection, Eur J Gastroenterol Hepatol, 31, 382, 10.1097/MEG.0000000000001299 · doi:10.1097/meg.0000000000001299
- 2018, Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African‐American patients: a community‐based retrospective cohort study, Eur J Gastroenterol Hepatol, 30, 1200, 10.1097/MEG.0000000000001233 · doi:10.1097/meg.0000000000001233
- 2018, Satisfactory virological response and fibrosis improvement of sofosbuvir‐based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real‐world cohort study, Virol J, 15, 150, 10.1186/s12985-018-1066-8 · doi:10.1186/s12985-018-1066-8
- 2006, The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10‐year period, J Pediatr, 148, 353, 10.1016/j.jpeds.2005.10.031 · doi:10.1016/j.jpeds.2005.10.031
- 2015, Hepatitis C virus (HCV) vertical transmission in 12‐month‐old infants born to HCV‐infected women and assessment of maternal risk factors, Open Forum Infect Dis, 2, ofv089, 10.1093/ofid/ofv089 · doi:10.1093/ofid/ofv089
- 2001, Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV‐seronegative pregnant women: a 24‐month prospective study, J Pediatr Gastroenterol Nutr, 33, 570
- 2012, Anti‐HCV testing as a basic standard of monitoring HCV mother‐to‐child infection: advantages and disadvantages of the method, Przegl Epidemiol, 66, 341
- 2005, Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV‐infected mothers, Acta Paediatr, 94, 444, 10.1111/j.1651-2227.2005.tb01916.x · doi:10.1111/j.1651-2227.2005.tb01916.x
- 2012, Spontaneous clearance of hepatitis C virus in vertically infected children, Eur J Pediatr, 171, 253, 10.1007/s00431-011-1517-3 · doi:10.1007/s00431-011-1517-3
- 2016, Hepatitis C viraemia after apparent spontaneous clearance in a vertically infected child, Lancet, 387, 1967, 10.1016/S0140-6736(16)00085-4 · doi:10.1016/s0140-6736(16)00085-4
- 2018, Polymerase chain reaction (PCR) for detection of vertically acquired hepatitis C virus (HCV) infection in early infancy, Open Forum Infect Dis, 5, S654
- 2009, Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes, J Pediatr Gastroenterol Nutr, 48, 341, 10.1097/MPG.0b013e318185998f · doi:10.1097/mpg.0b013e318185998f
- 2008, Health‐related quality of life in children with hepatitis C acquired in the first year of life, J Gastroenterol Hepatol, 23, 226, 10.1111/j.1440-1746.2007.04859.x · doi:10.1111/j.1440-1746.2007.04859.x
- 2017, Clinical usefulness of new noninvasive serum biomarkers for the assessment of liver fibrosis and steatosis in children with chronic hepatitis C, Clin Exp Hepatol, 3, 198
- 2016, Transient liver elastography in unsedated control children: impact of age and intercurrent illness, J Paediatr Child Health, 52, 637, 10.1111/jpc.13151 · doi:10.1111/jpc.13151
- 2013, Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston Children's Hospital experience, J Pediatr, 163, 1058, 10.1016/j.jpeds.2013.04.044 · doi:10.1016/j.jpeds.2013.04.044
- 2018, Epidemiologic features of 348 children with hepatitis C virus infection over a 30‐year period: a nationwide survey in Japan, J Gastroenterol, 53, 419, 10.1007/s00535-017-1351-0 · doi:10.1007/s00535-017-1351-0
- 2008, Long‐term course of chronic hepatitis C in children: from viral clearance to end‐stage liver disease, Gastroenterology, 134, 1900, 10.1053/j.gastro.2008.02.082 · doi:10.1053/j.gastro.2008.02.082
- 2010, Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection, J Pediatr Gastroenterol Nutr, 51, 191, 10.1097/MPG.0b013e3181d32756 · doi:10.1097/mpg.0b013e3181d32756
- 2011, Diagnosis and management of hepatitis C virus–infected children, Pediatr Infect Dis J, 30, 983, 10.1097/INF.0b013e318236ac37 · doi:10.1097/inf.0b013e318236ac37
- 2008, Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds‐C Trial, Hepatology, 47, 836, 10.1002/hep.22094 · doi:10.1002/hep.22094
- 2006, Hepatitis C in children: a quaternary referral center perspective, J Pediatr Gastroenterol Nutr, 43, 209, 10.1097/01.mpg.0000228117.52229.32 · doi:10.1097/01.mpg.0000228117.52229.32
- 2015, Histopathology of hepatitis C in children, a systematic review: implications for treatment, Expert Rev Anti Infect Ther, 13, 1225, 10.1586/14787210.2015.1070668 · doi:10.1586/14787210.2015.1070668
- 2013, Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study, Hepatology, 58, 1580, 10.1002/hep.26519 · doi:10.1002/hep.26519
- 2004, The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort, Blood, 103, 2460, 10.1182/blood-2003-07-2565 · doi:10.1182/blood-2003-07-2565
- 1998, Histopathology of the liver in children with chronic hepatitis C viral infection, Hepatology, 28, 1416, 10.1002/hep.510280534 · doi:10.1002/hep.510280534
- 1998, Chronic hepatitis C in children: the pathological and clinical spectrum, Gastroenterology, 115, 1525, 10.1016/S0016-5085(98)70032-0 · doi:10.1016/s0016-5085(98)70032-0
- 2019, Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study, Hepatology
- 2017, Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment‐experienced patients with chronic hepatitis C infection, Gastroenterology, 152, 164, 10.1053/j.gastro.2016.09.045 · doi:10.1053/j.gastro.2016.09.045
- 2018, Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis, Liver Int, 38, 1583, 10.1111/liv.13727 · doi:10.1111/liv.13727
- 2018, Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial, Hepatology, 67, 514, 10.1002/hep.29541 · doi:10.1002/hep.29541
- 2019, Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9‐12 years) and adolescents, Hepatol Int, 13, 706, 10.1007/s12072-019-09985-w · doi:10.1007/s12072-019-09985-w
- 2018, Sustained viral response in genotype 4 chronic hepatitis C virus–infected children and adolescents treated with sofosbuvir/ledipasvir, J Pediatr Gastroenterol Nutr, 67, 626, 10.1097/MPG.0000000000002101 · doi:10.1097/mpg.0000000000002101
- 2011, The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes, Aliment Pharmacol Ther, 33, 559, 10.1111/j.1365-2036.2010.04549.x · doi:10.1111/j.1365-2036.2010.04549.x
- 2017, Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure, Transpl Infect Dis, 19
- 2015, Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study, PLoS One, 10
- 2014, Dynamics of HCV RNA levels during acute hepatitis C virus infection, J Med Virol, 86, 1722, 10.1002/jmv.24010 · doi:10.1002/jmv.24010
- 2018, Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis, Hepatology, 67, 837, 10.1002/hep.29611 · doi:10.1002/hep.29611
- 2012, Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA‐licensed assays: implications for transfusion safety and HCV infection outcomes, Blood, 119, 6326, 10.1182/blood-2011-12-393637 · doi:10.1182/blood-2011-12-393637
- 2015, Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes, J Hepatol, 63, 586, 10.1016/j.jhep.2015.04.025 · doi:10.1016/j.jhep.2015.04.025
- 2008, The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy, J Viral Hepat, 15, 120, 10.1111/j.1365-2893.2007.00900.x · doi:10.1111/j.1365-2893.2007.00900.x
- 2019, Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir‐containing regimens without iInterferon for treatment of acute HCV in HIV‐1 infected individuals, Clin Infect Dis
- 2019, Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)–viremic donors into HCV‐negative recipients: outcomes following liver transplant of HCV‐viremic donors, Hepatology, 69, 2381, 10.1002/hep.30540 · doi:10.1002/hep.30540
- 2016, Improving organ utilization to help overcome the tragedies of the opioid epidemic, Am J Transplant, 16, 2836, 10.1111/ajt.13971 · doi:10.1111/ajt.13971
- 2019, National trends in utilization and 1‐year outcomes with transplantation of HCV‐viremic kidneys, J Am Soc Nephrol, 30, 1939, 10.1681/ASN.2019050462 · doi:10.1681/asn.2019050462
- 2018, Changes in utilization and discard of HCV antibody–positive deceased donor kidneys in the era of direct‐acting antiviral therapy, Transplantation, 102, 2088, 10.1097/TP.0000000000002323 · doi:10.1097/tp.0000000000002323
- 2015, Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts, Transplantation, 99, 1192, 10.1097/TP.0000000000000479 · doi:10.1097/tp.0000000000000479
- 2018, Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney, Transpl Infect Dis, 20
- 2018, Hepatitis C transmission from seropositive, nonviremic donors to non‐hepatitis C liver transplant recipients, Hepatology, 67, 1673, 10.1002/hep.29704 · doi:10.1002/hep.29704
- 2019, Possible acute rejection associated with the use of the new anti–hepatitis C virus medications, Avicenna J Med, 9, 32, 10.4103/AJM.AJM_171_17 · doi:10.4103/ajm.ajm_171_17
- 2018, The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies, Transplantation, 102, S325
- 2017, Efficacy and tolerability of interferon‐free antiviral therapy in kidney transplant recipients with chronic hepatitis C, J Hepatol, 66, 718, 10.1016/j.jhep.2016.12.020 · doi:10.1016/j.jhep.2016.12.020
- 2019, Impact of sofosbuvir‐based regimens for the treatment of hepatitis C after liver transplant on renal function: results of a Canadian national retrospective study, Exp Clin Transplant, 17, 59, 10.6002/ect.2017.0201 · doi:10.6002/ect.2017.0201
- 2018, Impact of anti‐HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid‐term follow‐up in a single‐center cohort study, Transpl Int, 31, 887, 10.1111/tri.13118 · doi:10.1111/tri.13118
- 2017, Direct‐acting antiviral agent‐based regimen for HCV recurrence after combined liver–kidney transplantation: results from the ANRS CO23 CUPILT study, Am J Transplant, 17, 2869, 10.1111/ajt.14490 · doi:10.1111/ajt.14490
- 2017, Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents, Transplantation, 101, 1704, 10.1097/TP.0000000000001618 · doi:10.1097/tp.0000000000001618
- 2019, Pre‐emptive pangenotypic direct acting antiviral therapy in donor HCV‐positive to recipient HCV‐negative heart transplantation: an open‐label study, Lancet Gastroenterol Hepatol, 4, 771, 10.1016/S2468-1253(19)30240-7 · doi:10.1016/s2468-1253(19)30240-7
- 2019, Fibrosing cholestatic hepatitis after kidney transplantation from HCV‐viremic donors to HCV‐negative recipients: a unique complication in the DAA era, Am J Transplant
- 2017, Favorable short‐term outcome of hepatitis C virus–positive liver graft with bridging fibrosis: a plea for very early viral eradication, Hepatology, 65, 2116, 10.1002/hep.28978 · doi:10.1002/hep.28978
- 2017, Transplanting HCV‐infected kidneys into uninfected recipients, N Engl J Med, 377, 1105
- 2017, Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor, Antimicrob Agents Chemother, 61
- 2018, The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype, Transpl Infect Dis, 20
- 2017, Drug–drug interactions in hepatitis C virus treatment: do they really matter?, Clin Liver Dis (Hoboken), 10, 111, 10.1002/cld.668 · doi:10.1002/cld.668
- 2017, Decreased tacrolimus plasma concentrations during HCV therapy: a drug–drug interaction or is there an alternative explanation?, Int J Antimicrob Agents, 49, 379, 10.1016/j.ijantimicag.2016.12.004 · doi:10.1016/j.ijantimicag.2016.12.004
- 2016, Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct‐acting antivirals as treatment for hepatitis C infection, Ther Drug Monit, 38, 640, 10.1097/FTD.0000000000000315 · doi:10.1097/ftd.0000000000000315
- 2015, Drug interactions with direct‐acting antivirals for hepatitis C: implications for HIV and transplant patients, Ann Pharmacother, 49, 674, 10.1177/1060028015576180 · doi:10.1177/1060028015576180
- 2019, HCV NAT positive solid organ allografts transplanted into HCV negative recipients: a real‐world experience, Hepatology
- 2019, Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era, J Heart Lung Transplant, 38, 907, 10.1016/j.healun.2019.06.023 · doi:10.1016/j.healun.2019.06.023
- 2012, Early viral load and recipient interleukin‐28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation, Liver Transpl, 18, 671, 10.1002/lt.23402 · doi:10.1002/lt.23402
Cited by
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Global epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Microfluidic Paper-Based Analytical Devices: From Design to Applications
Noviana, E., Ozer, T., Carrell, C. S., Link, J. S., McMahon, C., Jang, I., & Henry, C. S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01335 · Cited by 631
Metadata
- Authors
- Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G.
- Venue
- Hepatology
- Published
- 2020-02
- Volume
- 71
- Issue
- 2
- Pages
- 686-721
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2992772421
- Cited by
- 955
- References
- 271
- FWCI
- 66.55
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor, 9 d)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.